Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2026 08:05 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim licenses preclinical antibody program from Immunitas Therapeutics to advance treatments for chronic inflammatory diseases

Boehringer and Immunitas Therapeutics partner on a preclinical antibody program aimed at delivering more durable inflammatory disease control.